Similar articles

• Rationale for the intraperitoneal approach to surgical adjuvant chemotherapy of gastric cancer.

  Douglass HO Jr. Douglass HO Jr. Cancer Treat Res. 1991;55:41-50. doi: 10.1007/978-1-4615-3882-0_3. Cancer Treat Res. 1991. PMID: 1681868 Review. No abstract available.
• Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.

  Cascinu S, Galizia E, Labianca R, Ferraù F, Pucci F, Silva RR, Luppi G, Beretta GD, Berardi R, Scartozzi M. Cascinu S, et al. Cancer Chemother Pharmacol. 2011 Jul;68(1):37-43. doi: 10.1007/s00280-010-1424-8. Epub 2010 Sep 7. Cancer Chemother Pharmacol. 2011. PMID: 20821330 Clinical Trial.
• Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy.

  Sugarbaker PH, Stuart OA, Yoo D. Sugarbaker PH, et al. J Oncol Pharm Pract. 2005 Sep;11(3):111-9. doi: 10.1191/1078155205jp157oa. J Oncol Pharm Pract. 2005. PMID: 16390599 Review.
• Early postoperative intraperitoneal chemotherapy for gastric cancer.

  Yu WS, Sugarbaker PH. Yu WS, et al. Cancer Treat Res. 1991;55:265-75. doi: 10.1007/978-1-4615-3882-0_14. Cancer Treat Res. 1991. PMID: 1681860 Review. No abstract available.
• Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer.

  Fujita K, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M. Fujita K, et al. Anticancer Res. 1998 May-Jun;18(3B):1973-8. Anticancer Res. 1998. PMID: 9677452 Clinical Trial.